TARS Q4 2020 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$11M

Net Income

-$11M

EPS (Diluted)

$-0.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$438,000

Balance Sheet

Total Assets

$172M

Total Liabilities

$6M

Stockholders' Equity

$166M

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$11M	-$1M	-958.8%
Net Income	-$11M	-$1M	-712.1%